Target intelligence / Profile preview

Tubulin beta-6 chain (TUBB6)

Target
TUBB6
Molecular classification
Structural protein, Cytoskeletal protein, Microtubule subunit, Other
01

Overview

Tubulin beta-6 chain (TUBB6) is a structural protein encoded by the TUBB6 gene and a member of the beta-tubulin family, which, together with alpha-tubulin, forms microtubules—the major component of the eukaryotic cytoskeleton[3][5]. Microtubules are essential for cellular processes including mitosis, intracellular transport, and maintenance of cell shape[5]. TUBB6 is differentially expressed in various tissues, including muscle and brain, and is upregulated in several cancers[2][1]. Recent studies identify TUBB6 as a key biomarker and potential therapeutic target in glioblastoma and other cancers because its expression correlates with poor prognosis and altered cell proliferation[1]. As part of the microtubule system, TUBB6 is an indirect target of microtubule-binding drugs commonly used in cancer therapy, though isoform-selective targeting remains unrealized[5][1]. Overexpression of TUBB6 is also implicated in muscle pathologies such as muscular dystrophy by altering microtubule organization[4].

Other names
Tubulin beta 6 class VTUBB6Tubulin beta-6 chainMGC4083HsT1601Tubulin beta class Vtubulin beta MGC4083class V beta-tubulinFPVEPDTUBB-5tubulin, beta 6
02

Mechanism of action

Inhibitors/Disruptors of microtubule polymerization or depolymerization[5]. Blockade of mitosis via microtubule stabilization (taxanes) or destabilization (vinca alkaloids)[5].

03

Biological functions

Microtubule cytoskeleton organizationCell cycleCellular division (mitosis/meiosis)Cell proliferationCell developmentRegulation of coagulationPositive regulation of fibroblast proliferationMembrane biogenesisOsteoclast development and differentiationT cell proliferation
04

Disease associations

CancerNeurodegenerative disease (indirect)Muscle disease/atrophy (e.g., muscular dystrophy)Other
05

Safety considerations

General toxicities related to microtubule inhibitor drugs, including neurotoxicity, myelosuppression, peripheral neuropathy[5]Lack of TUBB6 isoform-selective drugs can lead to broad disruption of microtubule function in normal cells[5]
06

Interacting drugs

Taxanes (e.g., paclitaxel, docetaxel; class, not isoform-specific)

2 more in the full profile.

07

Biomarkers

Prognostic marker in glioblastoma (GBM), primary GBM, gastric, ovarian, prostate, and triple-negative breast cancer[1]Associated with prognosis in muscle disease (e.g., muscular dystrophy)[4]

Beyond the preview

Go deeper on Tubulin beta-6 chain (TUBB6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tubulin beta-6 chain (TUBB6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call